BR9816097A - Methods to treat an allergic reaction in a mammal, skin inflammation in a mammal, arthritis selected from the group consisting of osteoarthritis, psoriatic arthritis, lupus, and spondyloarthritis, chronic obstructive pulmonary disease in a patient, chronic inflammatory bowel disease in a patient , to inhibit the infiltration of eosinophils into a patient's airways, the release of mucosa into various areas of a patient, to block the lymphocyte's ige activation, to stabilize a lymphocyte's cell membrane, and to inhibit the migration of t-cells - Google Patents

Methods to treat an allergic reaction in a mammal, skin inflammation in a mammal, arthritis selected from the group consisting of osteoarthritis, psoriatic arthritis, lupus, and spondyloarthritis, chronic obstructive pulmonary disease in a patient, chronic inflammatory bowel disease in a patient , to inhibit the infiltration of eosinophils into a patient's airways, the release of mucosa into various areas of a patient, to block the lymphocyte's ige activation, to stabilize a lymphocyte's cell membrane, and to inhibit the migration of t-cells

Info

Publication number
BR9816097A
BR9816097A BR9816097-4A BR9816097A BR9816097A BR 9816097 A BR9816097 A BR 9816097A BR 9816097 A BR9816097 A BR 9816097A BR 9816097 A BR9816097 A BR 9816097A
Authority
BR
Brazil
Prior art keywords
patient
lymphocyte
inhibit
mammal
airways
Prior art date
Application number
BR9816097-4A
Other languages
Portuguese (pt)
Inventor
John C Houck
James Clagett
Original Assignee
Histatek Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histatek Llc filed Critical Histatek Llc
Publication of BR9816097A publication Critical patent/BR9816097A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODOS PARA TRATAR UMA REAçãO ALéRGICA EM UM MAMìFERO, INFLAMAçãO CUTâNEA EM UM MAMìFERO, ARTRITE SELECIONADA DO GRUPO QUE CONSISTE DE OSTEOARTRITE, ARTRITE PSORIáTICA, LUPUS, E ESPONDILARTRITE, DOENçA PULMONAR DE OBSTRUçãO CRÈNICA EM UM PACIENTE, DOENçA DE INTESTINO INFLAMATóRIA CRÈNICA EM UM PACIENTE, PARA INIBIR A INFILTRAçãO DE EOSINóFILOS EM VIAS AéREAS DE UM PACIENTE, A LIBERAçãO DE MUCOSA EM VIAS áREAS DE UM PACIENTE, PARA BLOQUEAR A ATIVAçãO IGE DE UM LINFóCITO, PARA ESTABILIZAR A MEMBRANA DA CéLULA DE UM LINFóCITO, E PARA INIBIR A MIGRAçãO DE CéLULAS-T". São descritos métodos para tratar alergias, inflamação cutânea, artrite, doença pulmonar de obstrução crónica e tratar doenças de intestino inflamatórias crónicas. Também é descrito um método para inibir a infiltração de eosinófilos em vias aéreas de um paciente, um método para inibir a liberação mucosa em vias aéreas de um paciente, um método para bloquear a ativação IgE de um linfócito, um método para estabilizar a membrana de célula de um linfócito, desse modo impedindo ainda seu envolvimento na resposta inflamatória aumentada a um desafio de antígeno IgE, e um método para inibir a migração de células-T. Tais métodos envolvem administração a dito paciente de uma quantidade terapeuticamente efetiva de um peptídeo possuindo a fórmula f-Met-Leu-X, em que X é selecionado do grupo consistindo de Tyr, Tyr-Phe, Phe-Phe e Phe-Tyr."METHODS FOR TREATING AN ALLERGIC REACTION IN A MAMMALIAN, CUTANEOUS INFLAMMATION IN A MAMMALIAN, SELECTED ARTHRITIS IN THE GROUP THAT CONSISTS OF OSTEOARTHRITIS, PSORIATIC ARTHRITIS, LUPUS, AND SPONDYLARCHES IN AN EMOTIONAL STRENGTH DISEASE PATIENT, TO INHIBIT EOSINOPHIL INFILTRATION IN A PATIENT'S AIRWAYS, MUCOUS RELEASE IN A PATIENT'S AIRWAYS, TO BLOCK THE IGE ACTIVATION OF A LYMPHOCYTE, TO STABILIZE THE LAMINATION CELL OF A LYMPH CELL, A LYMPH CELL OF A LYMPH CELL, AND A LYMPH CELL. OF T-CELLS ". Methods for treating allergies, skin inflammation, arthritis, chronic obstructive pulmonary disease, and treating chronic inflammatory bowel diseases are described. Also described is a method to inhibit the infiltration of eosinophils into a patient's airways, a method to inhibit mucosal release in a patient's airways, a method to block IgE activation of a lymphocyte, a method to stabilize the membrane of lymphocyte cell, thereby further preventing its involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting T-cell migration. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

BR9816097-4A 1998-12-03 1998-12-03 Methods to treat an allergic reaction in a mammal, skin inflammation in a mammal, arthritis selected from the group consisting of osteoarthritis, psoriatic arthritis, lupus, and spondyloarthritis, chronic obstructive pulmonary disease in a patient, chronic inflammatory bowel disease in a patient , to inhibit the infiltration of eosinophils into a patient's airways, the release of mucosa into various areas of a patient, to block the lymphocyte's ige activation, to stabilize a lymphocyte's cell membrane, and to inhibit the migration of t-cells BR9816097A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/025583 WO2000032217A1 (en) 1998-12-03 1998-12-03 Small peptides and methods for treatment of asthma and inflammation

Publications (1)

Publication Number Publication Date
BR9816097A true BR9816097A (en) 2002-01-22

Family

ID=22268409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9816097-4A BR9816097A (en) 1998-12-03 1998-12-03 Methods to treat an allergic reaction in a mammal, skin inflammation in a mammal, arthritis selected from the group consisting of osteoarthritis, psoriatic arthritis, lupus, and spondyloarthritis, chronic obstructive pulmonary disease in a patient, chronic inflammatory bowel disease in a patient , to inhibit the infiltration of eosinophils into a patient's airways, the release of mucosa into various areas of a patient, to block the lymphocyte's ige activation, to stabilize a lymphocyte's cell membrane, and to inhibit the migration of t-cells

Country Status (10)

Country Link
EP (1) EP1152770A1 (en)
JP (1) JP2003504304A (en)
KR (1) KR100596136B1 (en)
CN (1) CN1341026A (en)
AU (1) AU1801899A (en)
BR (1) BR9816097A (en)
CA (1) CA2353550A1 (en)
HK (1) HK1044468A1 (en)
MX (1) MXPA01005600A (en)
WO (1) WO2000032217A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840851D1 (en) 1997-11-13 2009-07-09 Mowycal Lending Llc SMALL PEPTIDES AND METHODS FOR THE TREATMENT OF ASTHMA AND IGNITION
EA200200169A1 (en) * 1999-07-16 2002-06-27 Хистатек, Ллс SMALL PEPTIDES AND METHODS OF DECREASING IgE REGULATION
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US9788821B2 (en) 2005-04-29 2017-10-17 Cook Biotech Incorporated Physically modified extracellular matrix materials and uses thereof
EP2358409B1 (en) 2008-06-20 2017-01-18 Cook Biotech Incorporated Compressible/expandable medical graft products, and methods for applying hemostasis
TW202342103A (en) * 2022-03-30 2023-11-01 耶魯大學 Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish)
KR20230141227A (en) * 2022-03-31 2023-10-10 (주)케어젠 Peptide Having Activity of Anti-Inflammation and Anti-Fibrosis and Uses Thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314680A (en) * 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
DE69840851D1 (en) * 1997-11-13 2009-07-09 Mowycal Lending Llc SMALL PEPTIDES AND METHODS FOR THE TREATMENT OF ASTHMA AND IGNITION

Also Published As

Publication number Publication date
CA2353550A1 (en) 2000-06-08
KR20010108002A (en) 2001-12-07
KR100596136B1 (en) 2006-07-05
WO2000032217A1 (en) 2000-06-08
HK1044468A1 (en) 2002-10-25
JP2003504304A (en) 2003-02-04
EP1152770A1 (en) 2001-11-14
CN1341026A (en) 2002-03-20
AU1801899A (en) 2000-06-19
MXPA01005600A (en) 2003-07-14

Similar Documents

Publication Publication Date Title
Naukkarinen et al. Quantification of cutaneous sensory nerves and their substance P content in psoriasis
Donoff et al. Preparation and properties of collagenases from epithelium and mesenchyme of healing mammalian wounds
KR970707141A (en) Tumor necrosis factor-gamma
ATE199645T1 (en) COMBINATION OF NECROSE-INDUCING SUBSTANCES WITH SUBSTANCES ACTIVATED BY NECROSES FOR SELECTIVE THERAPY OF TUMORS AND INFLAMMATORY DISEASES
NO932610D0 (en) METHOD OF AA PREVENTING OR TREATING TNF-INDUCED DISEASES
PT988301E (en) CICID ACIDS OF IMIDAZOLYL
DE69326064D1 (en) Human protein P53 peptides for use in human cytotoxic T cell response inducing compositions and human P53 protein specific T lymphocytes
BR9809115A (en) Methods to treat inflammation and inflammatory diseases using padprt inhibitors
BR9816097A (en) Methods to treat an allergic reaction in a mammal, skin inflammation in a mammal, arthritis selected from the group consisting of osteoarthritis, psoriatic arthritis, lupus, and spondyloarthritis, chronic obstructive pulmonary disease in a patient, chronic inflammatory bowel disease in a patient , to inhibit the infiltration of eosinophils into a patient's airways, the release of mucosa into various areas of a patient, to block the lymphocyte's ige activation, to stabilize a lymphocyte's cell membrane, and to inhibit the migration of t-cells
BR9711296A (en) Compound therapeutic process to inhibit the growth of cancer cells and pharmaceutical composition
IT1263013B (en) ESTERS OF L-CARNITINE AND ALCANOYL L-CARNITINE WITH GLYCOLIC ACID OR ITS ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH AS FOR THE TREATMENT OF SKIN DISEASES.
BR9815288A (en) Pharmaceutical composition, processes to inhibit mast cell degranulation, to treat asthma in a patient, to treat inflammation in a patient, to inhibit the release of cytokines in a patient, to inhibit the release of histamines in a patient, to inhibit the release of leukotrienes in a patient, to reduce the adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils to a site of inflammation in a patient, to reduce the production of ige antibodies at the site of inflammation in a patient, to inhibit increased vascular permeability in inflammation site in a patient, and to treat chronic inflammation in a patient.
DE60140960D1 (en) USE OF SERP-1 IN COMBINATION WITH AN IMMUNOSUP PRESSOR FOR THE TREATMENT OF ARTHRITIS
ES2187646T3 (en) PROCEDURES FOR THE TREATMENT OF INFLAMMATIONS AND CORRESPONDING COMPOSITIONS.
FR2403800A1 (en) SKIN TREATMENT COMPOSITION WITH ANTIVIRAL ACTIVITY
DK0482089T3 (en) Methods for the treatment of autoimmune uveoretnitis in humans
WO1988000833A2 (en) Antipyretic and anti-inflammatory peptides
BR9907990A (en) Sequence of oligonucleotides complementary to the thioredoxin or thioredoxin reductase genes and methods of using them to modulate cell growth
FR2766190B1 (en) NOVEL PEPTIDES AND POLYPEPTIDES USEFUL IN THE REGENERATION OF THE NERVOUS SYSTEM
DE69329760D1 (en) TREATMENT OF STOMACH AND COLUMN Ulcers WITH MORPHOGENES
Averbook et al. Purified native and recombinant human alpha lymphotoxin [tumor necrosis factor (TNF)-beta] induces inflammatory reactions in normal skin
Zavadak et al. Chronic urticaria as a manifestation of the late phase reaction
Sickler et al. Cutaneous necrosis associated with interferon α-2b
Gordon et al. Tumor necrosis factor inhibits a polymorphonuclear leukocyte-dependent airway edema in guinea pigs
Il'chevich et al. Effect of antihepatocytotoxic serum on cellular and intracellular regeneration of the pathologically changed liver

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.